The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohnʼs disease
Open accessAbstract
BACKGROUND: Fecal calprotectin and lactoferrin are promising noninvasive biomarkers for intestinal inflammation. In Crohn's disease (CD), during anti-TNF-alpha (TNF-alpha) treatment, the clinical significance of these markers has, however, been insufficiently explored. METHODS: Among CD patients receiving anti-TNF-alpha therapy we assessed the role of fecal calprotectin and lactoferrin as surrogate markers for mucosal healing. Before and 3 months after the beginning of anti-TNF-alpha induction, 15 patients underwent ileocolonoscopy with scoring of the Crohn's Disease Index of Severity (CDEIS). Fecal samples for calprotectin and for lactoferrin measurements were collected and the Crohn's Disease Activity Index (CDAI) was calculated at the time of the endoscopies and 2 and 8 weeks after the first treatment. RESULTS: The median CDEIS fell from 13.0 to 4.8 (P = 0.002) and CDAI from 158 to 68 (P = 0.005). Accordingly, the median fecal calprotectin concentration fell from 1173 microg/g to 130 microg/g (P = 0.001) and fecal lactoferrin from 105.0 microg/g to 2.7 microg/g (P = 0.001). Of the 15 patients, 11 (73%) showed an endoscopic response to treatment and 5 of these achieved endoscopic remission (CDEIS < 3). In those 5 patients the fecal calprotectin concentration declined from 1891 mug/g (range 813-2434) to 27 microg/g (13-130) and lactoferrin from 92.4 microg/g (35.5-235.6) to 1.9 microg/g (0.0-2.1). CONCLUSIONS: Compared to pretreatment values, concentrations of fecal calprotectin and lactoferrin after the anti-TNF-alpha treatment were significantly lower. During anti-TNF-alpha therapy these fecal neutrophil-derived proteins may thus be useful surrogate markers for mucosal healing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mucosal Healing in Inflammatory Bowel Disease: Results From a Norwegian Population-Based Cohort
Frøslie, K. F., Jahnsen, J., Moum, B. A., & Vatn, M. H. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.051 · Cited by 1,121
Cited by
Peyrin-Biroulet, L., Sandborn, W., Sands, B. E., Reinisch, W., Bemelman, W., Bryant, R. V., D'Haens, G., Dotan, I., Dubinsky, M., Feagan, B., et al. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.233 · Cited by 1,844
Van Assche, G., Dignass, A., Panes, J., Beaugerie, L., Karagiannis, J., Allez, M., Ochsenkühn, T., Orchard, T., Rogler, G., Louis, E., et al. (2010) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.12.003 · Cited by 1,453
Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease
Baert, F., Moortgat, L., Van Assche, G., Caenepeel, P., Vergauwe, P., De Vos, M., Stokkers, P., Hommes, D., Rutgeerts, P., Vermeire, S., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.09.056 · Cited by 830
Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease
DʼHaens, G., Ferrante, M., Vermeire, S., Baert, F., Noman, M., Moortgat, L., Geens, P., Iwens, D., Aerden, I., Van Assche, G., et al. (2012) · Inflammatory Bowel Diseases · doi:10.1002/ibd.22917 · Cited by 816
European evidence based consensus for endoscopy in inflammatory bowel disease
Annese, V., Daperno, M., Rutter, M. D., Amiot, A., Bossuyt, P., East, J., Ferrante, M., Götz, M., Katsanos, K. H., Kießlich, R., et al. (2013) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2013.09.016 · Cited by 815
The Medical Management of Paediatric Crohn’s Disease: an ECCO-ESPGHAN Guideline Update
van Rheenen, P. F., Aloi, M., Assa, A., Bronsky, J., Escher, J. C., Fagerberg, U. L., Gasparetto, M., Gerasimidis, K., Griffiths, A., Henderson, P., et al. (2021) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjaa161 · Cited by 729
Self-citationvan Rheenen, P. F., Van de Vijver, E., & Fidler, V. (2010) · BMJ · doi:10.1136/bmj.c3369 · Cited by 714
Mosli, M. H., Zou, G., Garg, S. K., Feagan, S. G., MacDonald, J. K., Chande, N., Sandborn, W. J., & Feagan, B. G. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.120 · Cited by 690
The Utility of Biomarkers in the Diagnosis and Therapy of Inflammatory Bowel Disease
Lewis, J. D. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.11.058 · Cited by 458
SIPPONEN, T., KÄRKKÄINEN, P., SAVILAHTI, E., KOLHO, K. ‐., NUUTINEN, H., TURUNEN, U., & FÄRKKILÄ, M. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03835.x · Cited by 324
Self-citationMeta-analysis: Fecal Calprotectin for Assessment of Inflammatory Bowel Disease Activity
Lin, J.-F., Chen, J.-M., Zuo, J.-H., Yu, A., Xiao, Z.-J., Deng, F.-H., Nie, B., & Jiang, B. (2014) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000057 · Cited by 296
Treat to Target: A Proposed New Paradigm for the Management of Crohn's Disease
Bouguen, G., Levesque, B. G., Feagan, B. G., Kavanaugh, A., Peyrin–Biroulet, L., Colombel, J., Hanauer, S. B., & Sandborn, W. J. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.09.006 · Cited by 294
Wright, E. K., Kamm, M. A., De Cruz, P., Hamilton, A. L., Ritchie, K. J., Krejany, E. O., Leach, S., Gorelik, A., Liew, D., Prideaux, L., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.01.026 · Cited by 280
Positioning and usefulness of biomarkers in inflammatory bowel disease
Sakurai, T., & Saruta, M. (2023) · Digestion · doi:10.1159/000527846 · Cited by 156
Manolakis, A. C., Kapsoritakis, A. N., Tiaka, E. K., & Potamianos, S. P. (2011) · Digestive Diseases and Sciences · doi:10.1007/s10620-010-1494-9 · Cited by 96
ECCO position on harmonisation of Crohn's disease mucosal histopathology
Magro, F., Sabino, J., Rosini, F., Tripathi, M., Borralho, P., Baldin, P., Danese, S., Driessen, A., Gordon, I. O., Iacucci, M., et al. (2022) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjac006 · Cited by 76
Metadata
- Authors
- Sipponen, T., Savilahti, E., Kärkkäinen, P., Kolho, K.-L., Nuutinen, H., Turunen, U., & Färkkilä, M.
- Venue
- Inflammatory Bowel Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-10
- Volume
- 14
- Issue
- 10
- Pages
- 1392-1398
- ISSN
- 1078-0998 (ISSN-L)
- OpenAlex
- W2073851206
- Cited by
- 236
- References
- 1
- FWCI
- 7.03
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.